Oxurion finalizes enrollment in study of DME drug
Belgian company Oxurion has finalized patient enrollment for the first part of a phase 2 diabetic macular edema study investigating a drug alternative to anti-VEGF therapy, the company announced in a press release.
The multicenter KALAHARI study is designed to evaluate the company’s leading drug candidate THR-149, a plasma kallikrein inhibitor, in patients who respond suboptimally to anti-VEGF therapy. Part A, which will enroll at least 18 patients, will determine the optimal dose to be used in part B.
“These data, if positive, will provide proof of concept and be a significant derisking event for the company,” Tom Graney, CFA, CEO of Oxurion, said in the release. “This patient population currently does not have adequate treatment options and represents a critical area of unmet medical need in the treatment of diabetic macular edema.”
Graney projected data from part A will be available by the end of 2021, while finalized results of part B, a double-masked, active-controlled study comparing THR-149 with aflibercept, are anticipated in 2023.